![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, July 20, 2020 11:54:47 AM
AstraZeneca total number of employees in 2018 was 64,400, a 5.4% increase from 2017.
AstraZeneca total number of employees in 2017 was 61,100, a 2.35% increase from 2016.
AstraZeneca total number of employees in 2016 was 59,700, a 2.93% decline from 2015.
SPX 6/11/20 SELL
TQQQ 3/24/20 BUY
Recent AZN News
- IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial • Business Wire • 06/25/2024 11:00:00 AM
- IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer • Business Wire • 06/17/2024 11:00:00 AM
- CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial • Business Wire • 06/16/2024 11:00:00 AM
- FARXIGA approved in the US for the treatment of pediatric type-2 diabetes • Business Wire • 06/12/2024 09:35:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/12/2024 02:14:48 PM
- TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer • Business Wire • 06/10/2024 11:00:00 AM
- I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer • PR Newswire (US) • 06/06/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 08:23:12 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 06/04/2024 02:02:42 PM
- Economic Worries May Lead To Weakness On Wall Street • IH Market News • 06/04/2024 01:10:54 PM
- AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024 • PR Newswire (US) • 06/04/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 02:29:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 02:23:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 10:35:43 AM
- TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial • Business Wire • 06/02/2024 06:32:00 PM
- IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo • Business Wire • 06/02/2024 12:05:00 PM
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy • Business Wire • 06/02/2024 12:00:00 PM
- Cellectis Reports Financial Results for First Quarter 2024 • GlobeNewswire Inc. • 05/28/2024 08:30:00 PM
- ダトポタマブ デルクステカン、 進行性非扁平上皮非小細胞肺癌患者に対する第III相TROPION-Lung01試験において、 化学療法と比較して臨床的に有意な全生存期間の改善を示す • Business Wire • 05/28/2024 01:06:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 10:15:06 AM
- Datopotamab-Deruxtecan zeigt in Phase-III-Studie TROPION-Lung01 klinisch signifikante Verbesserung des Gesamtüberlebens im Vergleich zur Chemotherapie bei Patienten mit fortgeschrittenem nicht squamösem, nicht kleinzelligem Lungenkrebs • Business Wire • 05/27/2024 08:55:00 PM
- Le datopotamab deruxtecan a montré une survie globale cliniquement significative par rapport à la chimiothérapie chez des patients atteints d'un cancer avancé du poumon non à petites cellules et non squameux • Business Wire • 05/27/2024 05:14:00 PM
- Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial • Business Wire • 05/27/2024 11:00:00 AM
- AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA) • Business Wire • 05/23/2024 05:52:00 PM
- AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA) • Business Wire • 05/23/2024 11:00:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM